Increasing Chemotherapy in Small-Cell Lung Cancer: From Dose Intensity and Density to Megadoses

Navigation menu

Small Cell Lung Cancer

Chemotherapy and small cell ung cancer

[GOOGLEFREETEXTUNIQ-5-7american diabetes association guidelines 2009]

There are several related dedicated pages:. No preoperative therapy is given. Exact days for parts of the regimen were not specified by Arriagada et al. This vinblastine schedule is extrapolated from regimen information in Table 1 in which vinblastine is said to be given "weekly from days 1 to 29" and "then every 2 weeks after day 43 until last cisplatin administration. Diabetes and avesil vindesine schedule is extrapolated from regimen information in Table 1 in which vindesine is said to be given "weekly from days 1 to 29" and "then every 2 weeks after day 43 until last cisplatin administration.

No systemic treatment after surgery. Placed here because one or more randomized clinical trials included a placebo or observation arm in this disease context. P aclitaxel, C arboplatin, R adiation T chemotherapy and small cell ung cancer. E toposide, P latinol Cisplatinchemotherapy and small cell ung cancer, R adiation T herapy. A tezolizumab, B cell genesys and prostate cancer, C arboplatin, P aclitaxel.

G emcitabine and C arboplatin GCb: G emcitabine and C ar b oplatin. LR mutation in exon B evacizumab, C arboplatin, Pac litaxel. Carboplatin, Pemetrexed, Pembrolizumab in advanced or metastatic non-small cell lung cancer. Patients could receive a maximum of 35 cycles. No active antineoplastic treatment. Placed here because one or more randomized clinical trials included a placebo arm in this disease context.

Note that while this arm was inferior in ATLAS, the authors note that, due to toxicity, the "two-drug maintenance regimen will not lead to a new postchemotherapy standard of care. No further antineoplastic treatment after first-line therapy.

In LUX-Lung 4 This is the PMDA-approved dose. While statistically inferior, the median PFS difference was only 0. Patients in Blumenschein et al. The FDA only provides recommendations for ramucirumab dosing. This is the PMDA-approved dose of docetaxel. While statistically superior, the median PFS difference was only 0. Vandetanib is continued until disease progression, unacceptable toxicity, or withdrawal of consent. Patients in CheckMate had squamous histology.

Patients in CheckMate had non-squamous histology. Retrieved from " https: Non-small cell lung cancer regimens Disease-specific pages Thoracic cancers. Navigation menu Personal tools Create account Log in. Views Read View source View history. This page was last modified Based on work by Chemotherapy and small cell ung cancer WarnerHemOnc.

Cisplatin, Docetaxel, Bevacizumab 2. Cisplatin, Gemcitabine, Bevacizumab 3. Cisplatin, Pemetrexed, Bevacizumab 4. Carboplatin, Paclitaxel, high-dose RT 3. Carboplatin, Paclitaxel, Cetuximab, high-dose RT. PacCBevchemotherapy and small cell ung cancer, then Maintenance Bev. PemCBevthen PemBev maint. Cisplatin, Gemcitabine, low-dose Bevacizumab. Cisplatin, Gemcitabine, standard-dose Bevacizumab.

Le Chevalier et al.

 

Chemotherapy and small cell ung cancer

.